In last decades, immunotherapies became more and more significant as a cancer treatment method. Many in vivo and in vitro studies have been conducted in the literature in order to determine the appropriate diagnostic and treatment methods for cancer. During the development of therapeutic vaccines, determination of vaccine concentration which is the beginning step of in vivo studies, is critical for the healthy progression of the studies. Breast cancer which occurs by uncontrolled proliferation as a result of exposure of healthy cells in breast tissue to factors such as DNA damage, UV, radiation, carcinogens and, various chemicals has a huge portion among the cancer types. In this study, for the first time, antigens generated by two different antigen preparation methods (autoclaving, freezing-thawing) using AU-565 / MCF-7 cell lines. Then, antigens derived from human breast cancer cell lines were applied alone and with different adjuvants (Polyoxidonium, Freund’s) to the J774 macrophage cell culture system and the L929 fibroblast cell line in order to investigate immunostimulant activity and cytotoxicity via Griess reagent and MTT test respectively. At the end of the 48th hour, the cell viability well will be examined and the most appropriate antigen-adjuvant combination and its concentration for vaccine preparation were determined. Among the antigen preparation methods, it was determined that the freeze-thaw method was more effective than the autoclave method, and the antigens prepared by the freeze-thaw method from the AU-565 and MCF-7 cell lines showed the highest immunostimulatory activity at a concentration of 160 µg/ml. Among the adjuvants, the immunostimulant effect of Freund's adjuvant was found to be higher. In the light of these results, the optimal vaccine concentration against breast cancer and the viability analysis of these concentrations were determined. All in all, it is thought that antibodies obtained from in vivo studies using the most appropriate antigen preparation method and the most appropriate vaccine concentration can be used in the diagnosis and treatment of breast cancer.
Breast cancer is the most common type of cancer among women and is the second most common cause of cancer-related deaths. It is caused by the uncontrolled proliferation of cells in the breast tissue as a result of various factors. For the treatment of breast cancer, chemical drugs are utilized generally. However, chemical cancer drugs have a cytotoxic effect on healthy cells. That causes dose limitation and a decrease in the effectiveness of the treatment. For this reason, herbal-based studies in the treatment of breast cancer become popular day by day. In the literature, the anticancer, anti-inflammatory, and antimicrobial properties of many plants have been analyzed and their effectiveness has been proven. Diindolylmethane (DIM) and indole-3-carbinol (I3C) molecules found in Elettaria Cardamomum (E. Cardamomum, Cardamom) plant, reduce metastasis, tumorigenesis, immunomodulation. It has been shown in the literature that they play a role in preventing the development of breast cancer via inducing apoptotic pathways in the breast cancer cell. Herein, it is aimed to prevent breast cancer development by applying cardamom extract and cardamom Extract-Freund's adjuvant combination to THP-1 human macrophage cell line and MCF-7 breast cancer cell line and to increase the efficiency of cardamom extract with the use of an adjuvant. As a result, it was determined that the cytotoxic effect of the cardamom Extract-Freund’s adjuvant combination on breast cancer cells was higher than the alone cardamom extract application. At the same time, it was determined that the toxic effect of Freund's adjuvant could be reduced by increasing the plant extract concentration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.